Phathom Pharmaceuticals (PHAT) EBITDA Margin (2023 - 2026)
Phathom Pharmaceuticals (PHAT) reported EBITDA Margin of -5.18% for Q2 2026, up 146.07 percentage points from -151.26% a year earlier and up 21.17 percentage points from the prior quarter.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) EBITDA Margin (2023 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Phathom Pharmaceuticals' EBITDA Margin came in at -16.75%, up 218.50 percentage points year-over-year; for FY2025, it came in at -91.00%, up 409.74 percentage points from FY2024.
- By year, EBITDA Margin came in at -500.75% in FY2024 (+23947.49 pp) and -24448.24% in FY2023.
- The Q2 2026 figure ranks as the highest quarterly EBITDA Margin in data going back to Q4 2023.
- Year over year, EBITDA Margin has now increased in each of the last seven quarters, with an average year-over-year change of +2182.62 percentage points over the last seven quarters.
- Per Business Quant data, the three quarters before Q2 2026 came in at -26.36% (Q1 2026), -10.07% (Q4 2025) and -30.53% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Phathom Pharmaceuticals | 587.90 Mn | -52.05 Mn | 59.18 Mn | -3.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.96% |
| Mar 31, 2026 | -24.91% |
| Dec 31, 2025 | -8.67% |
| Sep 30, 2025 | -28.97% |
| Jun 30, 2025 | -149.40% |
| Mar 31, 2025 | -273.47% |
| Dec 31, 2024 | -197.53% |
| Sep 30, 2024 | -428.18% |
| Jun 30, 2024 | -1,045.92% |
| Mar 31, 2024 | -3,622.70% |
| Dec 31, 2023 | -10,135.48% |
API Access
Phathom Pharmaceuticals EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=PHAT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "PHAT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=PHAT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();